Small Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.

Just 29% of patients listed a treatment-response goal among their top personal goals.

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non­–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).

This cross-sectional observational study found several factors associated with whether a patient had sufficient lung cancer risk factor documentation in the electronic health record.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

Final overall survival data were presented at the European Lung Cancer Congress in Copenhagen, Denmark.

Evidence-Based Oncology (EBO) spoke with Len Lichtenfeld, MD, the chief medical officer for Jasper Health and a board member with CancerCare.

A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics.

Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.

Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.

Assessing both physical and emotional functioning scales within cancer quality-of-life questionnaires at diagnosis may help predict survival in patients with lung cancer, a recent study found.

A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).

A recent study suggests that sleeve lobectomy is safe to perform in patients with non–small cell lung cancer who received neoadjuvant therapy.

The survival benefits of immune checkpoint inhibitors varied in young patients versus older patients with advanced non–small-cell lung cancer, a recent study found.

Different methods of DNA collection and needle sizes led to varied next-generation sequencing success rates among patients with lung cancer in a recent study.

A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups.

The FDA approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small-cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

Adherence to annual lung cancer screening was only 22.3% among more than 1 million patients who underwent baseline screening between 2015 and 2019, a study published in the journal CHEST found.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non–small-cell lung cancer with PD-L1 expression of 1% or higher.

Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC).

The authors identified 2 subgroups with non–small cell lung cancer (NSCLC) who had different responses to common cancer therapies.

The authors say newer treatment options for small cell lung cancer (SCLC) may lead to improvement in this area of high unmet need.

Overall survival and recurrence-free survival showed substantial improvement when physicians more closely followed quality recommendations for non–small cell lung cancer (NSCLC).

Artificial intelligence (AI) improved detection of actionable lung nodules without leading to higher rates of false positives, the study found.

The latest updates in non–small cell lung cancer (NSCLC) cover recommendations for diagnostics, staging, when to use biomarker testing, sequencing of therapeutic options, and the addition of new treatments.

The real-world oncology data and analytics company COTA has joined the Clinical Research Data Sharing Alliance, a nonprofit consortium that aims to accelerate progress in cancer therapy development.

A new study estimates that prescription of standard-of-care non–small-cell lung cancer (NSCLC) therapies is lower than expected in Medicaid programs, with significant variation between states.